RBC Capital Downgrades Valeant Pharmaceuticals (VRX) to Sector Perform
Tweet
Share
E-mail
Get Alerts VRX Hot Sheet
Price: $23.40 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Join SI Premium – FREE
RBC Capital downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Sector Perform with a price target of $85.00 (from $194.00).
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $65.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns
- Mercury Systems (MRCY) PT Raised to $120 at RBC Capital
- Wolverine World Wide (WWW) PT Raised to $20 at Williams Trading
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
